**Federal marijuana rescheduling to Schedule III under the Controlled Substances Act advanced in phases during 2026.** In December 2025, President Trump issued an executive order directing expedited rulemaking. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28. This action provided immediate regulatory relief for medical operators while leaving non-medical cannabis in Schedule I. A separate expedited administrative hearing on broader rescheduling of all marijuana began June 29, 2026, and concluded by July 15, 2026, following withdrawal of prior stalled proceedings. The hearing gathered evidence on medical use, abuse potential, and dependence criteria before an administrative law judge. Post-hearing steps include the ALJ’s recommended decision, review by the DEA Administrator and Attorney General, and potential publication of a final rule in the Federal Register. Trader consensus on rapid full rescheduling reflects the remaining procedural requirements, possible legal challenges, and historical timelines for DEA scheduling actions. Key variables include any delays in the post-hearing phase or shifts in agency priorities.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$796,389 Vol.
Mar 31, 2026
September 30
14%
December 31
25%
$796,389 Vol.
September 30
$0 Vol.
14%
December 31
$186,818 Vol.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling to Schedule III under the Controlled Substances Act advanced in phases during 2026.** In December 2025, President Trump issued an executive order directing expedited rulemaking. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28. This action provided immediate regulatory relief for medical operators while leaving non-medical cannabis in Schedule I.
A separate expedited administrative hearing on broader rescheduling of all marijuana began June 29, 2026, and concluded by July 15, 2026, following withdrawal of prior stalled proceedings. The hearing gathered evidence on medical use, abuse potential, and dependence criteria before an administrative law judge. Post-hearing steps include the ALJ’s recommended decision, review by the DEA Administrator and Attorney General, and potential publication of a final rule in the Federal Register.
Trader consensus on rapid full rescheduling reflects the remaining procedural requirements, possible legal challenges, and historical timelines for DEA scheduling actions. Key variables include any delays in the post-hearing phase or shifts in agency priorities.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$796,389শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling to Schedule III under the Controlled Substances Act advanced in phases during 2026.** In December 2025, President Trump issued an executive order directing expedited rulemaking. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28. This action provided immediate regulatory relief for medical operators while leaving non-medical cannabis in Schedule I.
A separate expedited administrative hearing on broader rescheduling of all marijuana began June 29, 2026, and concluded by July 15, 2026, following withdrawal of prior stalled proceedings. The hearing gathered evidence on medical use, abuse potential, and dependence criteria before an administrative law judge. Post-hearing steps include the ALJ’s recommended decision, review by the DEA Administrator and Attorney General, and potential publication of a final rule in the Federal Register.
Trader consensus on rapid full rescheduling reflects the remaining procedural requirements, possible legal challenges, and historical timelines for DEA scheduling actions. Key variables include any delays in the post-hearing phase or shifts in agency priorities.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$796,389শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Federal marijuana rescheduling to Schedule III under the Controlled Substances Act advanced in phases during 2026.** In December 2025, President Trump issued an executive order directing expedited rulemaking. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28. This action provided immediate regulatory relief for medical operators while leaving non-medical cannabis in Schedule I. A separate expedited administrative hearing on broader rescheduling of all marijuana began June 29, 2026, and concluded by July 15, 2026, following withdrawal of prior stalled proceedings. The hearing gathered evidence on medical use, abuse potential, and dependence criteria before an administrative law judge. Post-hearing steps include the ALJ’s recommended decision, review by the DEA Administrator and Attorney General, and potential publication of a final rule in the Federal Register. Trader consensus on rapid full rescheduling reflects the remaining procedural requirements, possible legal challenges, and historical timelines for DEA scheduling actions. Key variables include any delays in the post-hearing phase or shifts in agency priorities.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা